After #ASH22: Post-mortem analysis on biggest Twitter buzz around drugs, studies and biopharmas
The American Society of Hematology (ASH) conference ended Tuesday and is the “most comprehensive hematology event of the year,” so it’s no surprise that Twitter was abuzz with the hematology and blood cancer research and drug news this week. But what got the biggest buzz? GlobalData’s post-mortem analysis broke out the leading topics, themes and influencers from ASH on Twitter.
Among the top biopharma companies trending were bluebird bio, Adaptive Biotech, AstraZeneca and Arcellx. The corporate Twitter posts promoted hematology and blood cancer science commitments, and presented research or invited attendees to stop by company booths for a visit.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.